Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma

This publication has 18 references indexed in Scilit:

• Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients
  Annals of Surgical Oncology, 2016
• Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
  Cancer Research, 2015
• Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor–positive salivary gland cancers
  Head & Neck, 2014
• Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: High rate of systemic failure warrants targeted therapy
  Oral Oncology, 2014
• AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
  New England Journal of Medicine, 2014
• Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways
  Cancer Research, 2014
• Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database
  Head & Neck, 2013
• Differential Expression of Hormonal and Growth Factor Receptors in Salivary Duct Carcinomas
  American Journal of Surgical Pathology, 2007
• Clinical and immunohistologic typing of salivary duct carcinoma
  Cancer, 2005
• Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
  Cancer, 2002